

REMARKS

The Official Action of September 19, 2007, and the references cited therein have been carefully considered. The Applicant respectfully requests reconsideration of the application in view of the following remarks. No claims have been amended.

1. Claims 21-35 are pending in the application.
2. Applicants acknowledge the Examiners consideration of the Information Disclosure Statement.
3. Claims 21-33 stand rejected under 35 U.S.C. 102 (b) as being anticipated by Simay et al. (CAS Abstract accession number 1981:442979).

Applicants respectfully traverse this rejection and submit that Simay et al. does not disclose each and every element of the invention. In particular, Simay et al. does not disclose that the elected compound has activity as an allosteric modulator of the mGluR5 receptor. Nor does Simay et al. disclose that the elected compound would be useful for treating schizophrenia or anxiety in a patient.


Applicants also respectfully submit that the disclosure of Simay et al. is not enabling. The information disclosed in Simay et al. (CAS Abstract accession number 1981:442979) would not have enabled one of ordinary skill in the art to prepare the compounds disclosed therein. Based on the very limited information regarding preparation of the compounds therein, it would have required undue experimentation for one of ordinary skill in the art to prepare the compounds disclosed by Simay et al.

Accordingly, the rejection of Claims 21-33 under 35 U.S.C. § 102(b) as being anticipated by Simay et al. is untenable and should be withdrawn.

Serial No.: 10/572,772
Case No.: 21370P
Page 3

Applicants respectfully contend that the application is allowable and a favorable response from the Examiner is earnestly solicited.

Respectfully submitted,

By 
J. Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: December 18, 2007